Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuka Kasamatsu

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|February 5, 2021
Pseudo-Meigs's syndromeEriko Miyawaki, Tateaki Naito, Yuka Kasamatsu
Journal of Gynecologic Oncology|June 4, 2021
A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trialKensuke Hori, Shin Nishio, Kimio Ushijima, et al.
The Journal of Obstetrics and Gynaecology Research|February 13, 2017
The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A reviewMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
The Journal of Obstetrics and Gynaecology Research|July 17, 2015
Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancerMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
Biomed Research International|October 2, 2015
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic TherapyMasakazu Abe, Yuka Kasamatsu, Nobuhiro Kado, et al.
International Journal of Clinical Oncology|February 10, 2016
Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomyMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical CancerAna Oaknin, Sharad A Ghamande, Yuka Kasamatsu, et al.
International Journal of Clinical Oncology|May 19, 2021
Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovaryEtsuko Miyagi, Noriaki Arakawa, Kentaro Sakamaki, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 2, 2015
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trialMasakazu Abe, Yasuyuki Hirashima, Yuka Kasamatsu, et al.
World Journal of Surgical Oncology|July 19, 2017
Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402)Tomoko Hirakawa, Takeo Minaguchi, Yoshio Itani, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|February 5, 2021
Pseudo-Meigs's syndromeEriko Miyawaki, Tateaki Naito, Yuka Kasamatsu
Journal of Gynecologic Oncology|June 4, 2021
A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trialKensuke Hori, Shin Nishio, Kimio Ushijima, et al.
The Journal of Obstetrics and Gynaecology Research|February 13, 2017
The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A reviewMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
The Journal of Obstetrics and Gynaecology Research|July 17, 2015
Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancerMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
Biomed Research International|October 2, 2015
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic TherapyMasakazu Abe, Yuka Kasamatsu, Nobuhiro Kado, et al.
International Journal of Clinical Oncology|February 10, 2016
Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomyMunetaka Takekuma, Yuka Kasamatsu, Nobuhiro Kado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical CancerAna Oaknin, Sharad A Ghamande, Yuka Kasamatsu, et al.
International Journal of Clinical Oncology|May 19, 2021
Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovaryEtsuko Miyagi, Noriaki Arakawa, Kentaro Sakamaki, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 2, 2015
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trialMasakazu Abe, Yasuyuki Hirashima, Yuka Kasamatsu, et al.
World Journal of Surgical Oncology|July 19, 2017
Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402)Tomoko Hirakawa, Takeo Minaguchi, Yoshio Itani, et al.
Pageof 1